Vernalis receives 1.5m dollar payment through Genentech collaboration
AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group.
AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group.
The collaboration, which commenced in January 2012, aims to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.
Ian Garland, Chief Executive Officer of Vernalis, commented: "We are delighted to have achieved this success milestone under our collaboration with Genentech which further endorses the quality of our research group's work."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Vernalis' share price was up 1.59% to 24p at 11:38 on Monday.
Vernalis develops and commercialises low-risk late stage products for unmet medical need.
MF
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Live: Did UK inflation rise in December? What to expect from tomorrow’s report
December’s inflation report will be published at 7.00am tomorrow. The team at MoneyWeek is reporting live.
By Katie Williams Last updated
-
Newspaper baron David Montgomery to bid for The Telegraph
Veteran media mogul David Montgomery has seen off a bid for his media group National World. But he now has his eye on The Telegraph
By Jane Lewis Published